Report Highlights
Including: 1) By Blood Cancer Type: Leukemia; Lymphoma
2) By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin)
3) By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic
Covering: Amgen Inc.; AstraZeneca PLC; Bayer AG; Celgene Corporation; Eli Lilly
Blood Cancer Drugs Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on blood cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for blood cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood cancer drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Report Synopsis
Report Metrics | Details |
Base year considered | 2022 |
Forecast period considered | 2022-2032 |
Units considered | $ Billion |
Segments covered | By Blood Cancer Type, By Drugs, By Treatment Approaches |
Industry covered | Pharmaceuticals |
Regions covered | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
Countries covered | Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. |
Companies studied |
|
Scope
Markets Covered:
- By Blood Cancer Type: Leukemia; Lymphoma
- By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Other Drugs
- By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic
Companies Mentioned: Amgen Inc.; AstraZeneca PLC; Bayer AG; Celgene Corporation; Eli Lilly
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
- Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Table 3 : Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 4 : Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 5 : Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 6 : Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 7 : Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 8 : Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 9 : Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 10 : China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 11 : China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 12 : India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 13 : India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 14 : Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 15 : Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 16 : Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 17 : Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 18 : Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 19 : Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 20 : South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 21 : South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 22 : Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 23 : Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 24 : UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 25 : UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 26 : Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 27 : Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 28 : France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 29 : France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 30 : Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 31 : Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 32 : Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 33 : Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 34 : North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 35 : North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 36 : USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 37 : USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 38 : South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 39 : South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 40 : Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 41 : Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 42 : Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 43 : Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 44 : Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 45 : Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 46 : Amgen Inc. Financial Performance
- Table 47 : AstraZeneca PLC Financial Performance
- Table 48 : Bayer AG Financial Performance
- Table 49 : Celgene Corporation Financial Performance
- Table 50 : Eli Lilly Financial Performance
- Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Figure 3 : Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 4 : Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 5 : Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 6 : Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 7 : Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 8 : Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 9 : Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 10 : China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 11 : China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 12 : India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 13 : India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 14 : Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 15 : Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 16 : Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 17 : Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 18 : Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 19 : Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 20 : South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 21 : South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 22 : Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 23 : Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 24 : UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 25 : UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 26 : Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 27 : Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 28 : France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 29 : France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 30 : Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 31 : Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 32 : Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 33 : Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 34 : North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 35 : North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 36 : USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 37 : USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 38 : South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 39 : South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 40 : Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 41 : Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 42 : Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 43 : Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 44 : Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 45 : Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 46 : Amgen Inc. Financial Performance
- Figure 47 : AstraZeneca PLC Financial Performance
- Figure 48 : Bayer AG Financial Performance
- Figure 49 : Celgene Corporation Financial Performance
- Figure 50 : Eli Lilly Financial Performance
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Similar Reports from TBRC (Publisher)
Blood Cancer Drugs Global Market Report 2022
Including: 1) By Blood Cancer Type: Leukemia; Lymphoma
2) By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Others
3) By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic
Covering: Amgen Inc.; AstraZeneca PLC.; Bayer AG; Celgene Corporation; Eli Lilly; Johnson & Johnson; Novartis; Pfizer Inc.; AbbVie ...
Blood Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030
Including: 1) By Blood Cancer Type: Leukemia; Lymphoma; Myeloma
2) By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Others
3) By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic
Covering: Amgen Inc.; AstraZeneca PLC; Bayer AG; Celgene Corporation; Eli Lilly
Blood Cancer Drugs Global Market ...
Blood Cancer Drugs Global Market Report 2020
Including: 1) By Blood Cancer Type: Leukemia, Lymphoma, Myeloma 2) By Drugs: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
Covering: Amgen Inc.,, AstraZeneca PLC,, Bayer AG,, Celgene Corporation,, Eli Lilly,
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More